5.97

5.01% 0.285

Kyverna Therapeutics Inc (KYTX)

Overview News Price History Option Chain Financials Discussions Forecast

Kyverna Therapeutics Inc stock is traded at $5.97, with a volume of 779.42K. It is up +5.01% in the last 24 hours and down -14.22% over the past month. Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Previous Close:

$5.685

Open:

$5.67

24h Volume:

779.42K

Relative Volume:

0.84

Market Cap:

$369.21M

Revenue:

$282.00K

Net Income/Loss:

$-156.40M

P/E Ratio:

-1.8202

EPS:

-3.2799

Net Cash Flow:

$-151.53M

1W Performance:

-3.40%

1M Performance:

-14.22%

6M Performance:

-36.49%

1Y Performance:

-17.77%

1-Day Range:

$5.67

$6.02

1-Week Range:

$5.61

$6.58

52-Week Range:

$5.61

$13.67

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Name

Kyverna Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(510) 626-8331

Address

5980 HORTON STREET, EMERYVILLE

Employee

130

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

KYTX's Discussions on Twitter

Compare KYTX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYTX Kyverna Therapeutics Inc	5.97	369.21M	282.00K	-156.40M	-151.53M	-3.2799
VRTX Vertex Pharmaceuticals Inc	508.75	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.34	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.27	53.22B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.08	42.32B	5.76B	514.49M	1.10B	4.4813

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-25	Initiated	William Blair	Outperform
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-10-24	Initiated	UBS	Buy
Oct-09-24	Initiated	Rodman & Renshaw	Buy
Jul-03-24	Initiated	H.C. Wainwright	Neutral
Mar-04-24	Initiated	JP Morgan	Overweight
Mar-04-24	Initiated	Leerink Partners	Outperform
Mar-04-24	Initiated	Morgan Stanley	Overweight
Mar-04-24	Initiated	Wells Fargo	Overweight

View All

Kyverna Therapeutics Inc Stock (KYTX) Latest News

Oct 06, 2026

Kyverna Therapeutics (Nasdaq:KYTX)Stock Analysis - Simply Wall Street

Oct 06, 2026

Oct 03, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat

Oct 03, 2026

Sep 13, 2026

KYTX Form 4 FilingsKyverna Therapeutics, Inc. SEC Form 4 - Stock Titan

Sep 13, 2026

Sep 09, 2026

Kyverna at wells fargo healthcare conference: autoimmune car t push advances - Investing.com Canada

Sep 09, 2026

Kyverna at wells fargo healthcare conference: autoimmune car t push advances - Investing.com India

Sep 09, 2026

Kyverna at wells fargo healthcare conference: autoimmune car t push advances - Investing.com

Sep 09, 2026

Kyverna at wells fargo healthcare conference: autoimmune car t push advances - Investing.com UK

Sep 09, 2026

KYTX: Miv-cel shows unprecedented efficacy in SPS, with regulatory and commercial milestones set for 2027 - TradingView

Sep 09, 2026

Sep 08, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 08, 2026

Sep 03, 2026

BlackRock Inc. Purchases Shares of 3,134,807 Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Sep 03, 2026

Sep 02, 2026

Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - theglobeandmail.com

Sep 02, 2026

Kyverna Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Sep 02, 2026

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts - BioPharma Dive

Sep 02, 2026

Kyverna Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance

Sep 02, 2026

Aug 24, 2026

Kyverna (KYTX): Posts a 3.09% Loss to $8.16 at the Close; Chart Watch: the Session Ends Within the Reported Technical Boundaries in the Latest SessionResistance Breakout Stocks - vinanet.vn

Aug 24, 2026

Aug 20, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.3%Time to Sell? - MarketBeat

Aug 20, 2026

Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis - CGTLive®

Aug 20, 2026

Aug 18, 2026

Kyverna (KYTX) Latest Reading: Declines 5.03% to $8.50 in the Latest Session; Session Range View: the Session Ends Within the Reported Technical Boundaries in the Available RecordDay Trade Opportunities - vinanet.vn

Aug 18, 2026

Kyverna Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 18, 2026

Aug 17, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.7% HigherShould You Buy? - MarketBeat

Aug 17, 2026

AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 17, 2026

Aug 15, 2026

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 15, 2026

Aug 14, 2026

KYTX Edges Higher: Kyverna Therapeutics Climbs 1.11% to $8.17Fibonacci Retracement - Vinanet

Aug 14, 2026

KYTX Edges Higher: Kyverna Therapeutics Climbs 1.11% to $8.17Fair Value Gap - dars.gov.et

Aug 14, 2026

Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat

Aug 14, 2026

Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan

Aug 14, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 14, 2026

Aug 13, 2026

KYTX Q1 2026 Earnings: Narrower-than-Expected Loss of -0.66 per Share Highlights Clinical-Stage Cost Discipline - vinanet.vn

Aug 13, 2026

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha

Aug 13, 2026

Aug 12, 2026

H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Aug 12, 2026

Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat

Aug 12, 2026

Aug 11, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Aug 11, 2026

Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade

Aug 11, 2026

Kyverna Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 11, 2026

Kyverna Therapeutics Announces Q2 2026 Financial Results and Operational Update - Kalkine Media

Aug 11, 2026

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - The Manila Times

Aug 11, 2026

KYTX: Q2 2026 net loss narrowed to $38.3M as miv-cel advanced toward commercialization - TradingView

Aug 11, 2026

Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan

Aug 11, 2026

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - GlobeNewswire

Aug 11, 2026

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - Yahoo Finance

Aug 11, 2026

FDA designation puts Kyverna’s one-dose cell therapy in focus for progressive MS - Stock Titan

Aug 11, 2026

Aug 09, 2026

Renaissance Technologies LLC Grows Stock Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 09, 2026

Aug 07, 2026

Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a shareEarnings Preview - TradingView

Aug 07, 2026